2014 YEAR IN REVIEW KEY INITIATIVES FINANCIALS £50M CRT’s cumulative return to CRUK surpassed this milestone in 2014 £28.8M Co-funding Joint CRUK-MEDI Launch of Ximbio, scheme with Bayer Alliance Laboratory an online portal for launched established research reagents Industry funds leveraged by CRT to support CRUK PROJECT DEVELOPMENT projects over the Scientists past two years visited MAJOR DEALS Deals completed Jan 2014 Collaboration between CRT, ICR and Nuevolution to screen potential cancer drugs Patents filed New projects sourced = 10 EARLY DIAGNOSIS DRUG DISCOVERY PILOT PHASE aPKC 5th Following the successful completion of a pilot phase, three new companies join an alliance between Cancer Research UK, CRT and Abcodia to identify blood markets for early cancer diagnosis FUNDING INITIATIVES PROJECT CRT and Teva’s collaboration yields successful outcome with novel aPKC protein inhibitor cancer drug discovery candidate. FORMA DUBs alliance successfully extended into second year The number of investments by the CRT Pioneer Fund (CPF) increases to five, including an investment to develop lung cancer drugs at the CRUK Manchester Institute. BACIT joins CPF and commits £20m CRT is dedicated to ‘Advancing Discoveries to Beat Cancer’ August 2014 CRUK, CRT and Astellas to conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer September 2014 Inivata, a new spin-out arising from the CRUK Cambridge Institute at the University of Cambridge, raises £4m in funding round October 2014 CRUK and LLR team up to boost blood cancer trials November 2014 CRUK drug discovery investigators to be given access to AstraZeneca screening facilities OUR PIPELINE DEVELOPMENT STAGE Key progressions: AGENT/TARGET PRECLINICAL PHASE I PHASE II PHASE III MARKET Temodal® Zytiga® RG7813 Drug based on a Cancer Research UK discovery, progressed into a Phase 1 trial by Roche (March 2014) Erivedge™ PARP TG4010 HSP90 SG 2000 GSK1070916A The first trial to conclude under the Clinical Developments Partnerships (CDP) initiative (March 14) Akt/PKB GSK1070916A IMA950 PI 3-kinase ONX-0801 IMA950 AT 13148 The first CDP project to complete a clinical trial and be taken forward by the company for further development (April 2014) AZD 0424 AZD 3965 DI-B4 RG7813 Undisclosed BTH1704 Cancer Research UK generated antibody taken into a Phase 1 trial in pancreatic cancer by Biothera (October 2014) AZD2098 CRT PROJECT AST-VAC2 CDP PROJECT As of Oct 2014 INDUSTRY INTERACTONS OUR OFFICES More than 150 face-to-face meetings held with leading pharma, biotech, tech transfer offices and investment funds at key industry events in 2014 BUZZ GENERATED 61% increase in Twitter followers. Join the discussion @CRT_News AND FINALLY CRT Head Office CRT-DL London CRT-DL Cambridge CRT Inc. December 2014: CRT-DL London moved to the London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH T: +44 (0)20 3469 6300 E: [email protected] 100+ cakes eaten by the CRT team during SU2C Icons made by Freepik from Flaticon licensed by Creative Commons BY 3.0 Social Infographics Elements Vector by Vector Open Stock. 26.2 miles our CSO Clive will be running in the 2015 London Marathon, in support of CRUK www.cancertechnology.com
© Copyright 2024 ExpyDoc
